Women's and men's health is the biggest story in digital health. We've built a profitable engine — now we're pointing it at Australia's two largest patient-pay markets.
Australians pay out of pocket, every month, for clinician-led care the mainstream system doesn't deliver. The category just produced a billion-dollar exit.
We start with the playbook proven and a profitable engine already running.
Herbly took the group properly live in April 2025. Twelve months later it's a profitable, repeatable operation.
Each new brand is a fresh front-end on infrastructure we've already built, paid for and proven.
Two are live today — visit them below, or tap any brand to expand.
~$3.6M run-rate, 2,300+ patients, profitable per script. The brand that proved Australians will pay for clinician-led telehealth.
Riding Australia's shift to a clinician-led model for nicotine vaping — a fresh front-end on the same engine.
Medical weight management and hormonal care — the Juniper model, localised. Our largest market: mostly self-funded, mostly women.
The male counterpart — weight, metabolic and hormonal health, on the same proven engine and warm patient base.
Practitioner-led medical weight management and hormonal & menopause care, delivered as a supported, recurring subscription — clinical treatment plus coaching, an app, community and discreet delivery. The largest patient-pay category, mostly self-funded, mostly women. We launch with the clinical engine, pharmacy and 2,300 warm patients already in place.
A ~$1.6B exit just validated the exact playbook in Australia.
Our engine is already live and profitable — not a concept.
No PBS subsidy means demand is paid out of pocket and recurring.
Two brands launching into peak category demand.
A small, hand-picked round to launch herkind and accelerate a model that already works.
Use of funds: the herkind launch and performance marketing, plus working capital through to group profitability. C-class: non-voting, same rights as the existing register — full dividends and surplus.
Minimum 1 share ($25k) · 10 shares available (5 further reserved at the company's discretion) · personal offer under s708 to sophisticated/wholesale investors.
The same simple process around 25 C-class shareholders have already been through.
Reply with the number of shares you'd like, plus the name or entity the shares will be held under, your TFN or ABN, and a mailing address.
We send the documents for e-signing via Adobe eSign — the same set every existing C-class shareholder has signed. Happy to walk through any clause on a call.
On receipt of funds, our accountants (SM Accounting Solutions) update the share register, lodge the issue with ASIC and issue your official share certificate — typically 5–10 business days.
Tap to see how each is managed.
Practitioner-led prescribing of TGA-approved treatments — a compliant, clinical model.
Ahpra-compliant synchronous consults and a clinical governance framework.
New brands launch on a proven engine with warm cross-sell, not from zero.
An 11-person team with documented systems. C-class shares are private; returns via performance, dividends and eventual exit, with pre-emption rights.
Happy to walk through the cap table, financials and the herkind launch plan in detail. No pressure either way.
Request a conversation →
